A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of pembrolizumab on the duration of remission in acute
myeloid leukemia. Pembrolizumab is given after complete remission is obtained in those with
AML at least 60 years old who are not candidates for allogeneic stem cell transplant. The
primary purpose of this study is determine if the time to relapse can be extended.
Additionally, the safety and tolerability of pembrolizumab will be closely monitored.